Paratek Pharmaceuticals Inc (PRTK.OQ)
PRTK.OQ on NASDAQ Stock Exchange Global Market
10.30USD
24 Apr 2018
10.30USD
24 Apr 2018
Change (% chg)
$-0.55 (-5.07%)
$-0.55 (-5.07%)
Prev Close
$10.85
$10.85
Open
$10.85
$10.85
Day's High
$10.85
$10.85
Day's Low
$10.20
$10.20
Volume
240,690
240,690
Avg. Vol
100,334
100,334
52-wk High
$29.00
$29.00
52-wk Low
$10.20
$10.20
Consensus Recommendations
Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
---|---|---|---|
Buy | -0.91 | December | 25 Apr 2018 |
Analyst Recommendations and Revisions
1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
---|---|---|---|---|
(1) BUY | 6 | 6 | 7 | 7 |
(2) OUTPERFORM | 4 | 4 | 2 | 3 |
(3) HOLD | 0 | 0 | 0 | 0 |
(4) UNDERPERFORM | 0 | 0 | 0 | 0 |
(5) SELL | 0 | 0 | 0 | 0 |
No Opinion | 0 | 0 | 0 | 0 |
Mean Rating | 1.40 | 1.40 | 1.22 | 1.30 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
# of Estimates | Mean | High | Low | 1 Year Ago |
|
---|---|---|---|---|---|
SALES (in millions) | |||||
Quarter Ending Jun-18 | 9 | 0.04 | 0.30 | 0.00 | -- |
Quarter Ending Sep-18 | 9 | 4.92 | 20.30 | 0.00 | -- |
Year Ending Dec-18 | 10 | 15.57 | 70.10 | 0.00 | 26.47 |
Year Ending Dec-19 | 9 | 48.52 | 185.30 | 12.50 | 53.60 |
Earnings (per share) | |||||
Quarter Ending Jun-18 | 8 | -0.91 | -0.77 | -1.11 | -- |
Quarter Ending Sep-18 | 8 | -0.77 | -0.29 | -1.12 | -- |
Year Ending Dec-18 | 9 | -3.26 | -1.45 | -4.13 | -2.79 |
Year Ending Dec-19 | 9 | -2.65 | 0.21 | -4.03 | -2.28 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
---|---|---|---|---|
SALES (in millions) | ||||
Quarter Ending Dec-17 | 3.12 | 5.07 | 1.95 | 62.30 |
Quarter Ending Sep-17 | 0.55 | 0.01 | 0.54 | 97.82 |
Quarter Ending Jun-17 | 2.89 | 7.51 | 4.63 | 160.23 |
Quarter Ending Mar-17 | 0.00 | 0.02 | 0.02 | 0.00 |
Quarter Ending Dec-16 | 0.00 | 0.03 | 0.03 | 0.00 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
---|---|---|---|---|---|
SALES (in millions) | |||||
Quarter Ending Jun-18 | 0.04 | 0.04 | 0.04 | 0.00 | -- |
Quarter Ending Sep-18 | 4.92 | 4.92 | 4.92 | 2.40 | -- |
Year Ending Dec-18 | 15.57 | 15.57 | 14.86 | 15.23 | 26.47 |
Year Ending Dec-19 | 48.52 | 48.52 | 48.64 | 53.12 | 53.60 |
Estimates Revisions Summary
Last Week | Last 4 Weeks | |||
---|---|---|---|---|
Number Of Revisions: | Up | Down | Up | Down |
Revenue | ||||
Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
Year Ending Dec-18 | 0 | 0 | 0 | 0 |
Year Ending Dec-19 | 0 | 0 | 0 | 1 |
Earnings |
- BRIEF-Paratek Pharmaceuticals Prices $140 Mln Of Convertible Senior Subordinated Notes Due 2024
- BRIEF-Paratek Pharmaceuticals Announces Proposed Private Offering Of $125 Mln Of Convertible Senior Subordinated Notes Due 2024
- BRIEF-Paratek Appoints Rolf Hoffman To Co's Board Of Directors
- BRIEF-Paratek's New Drug Applications For Oral And Intravenous Omadacycline Accepted For Priority Review By FDA
- BRIEF-Paratek Pharmaceuticals Reports Q4 Loss Per Share $0.78